{"id":"atorvastatin-esomeprazole","safety":{"commonSideEffects":[{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Myalgia"},{"rate":null,"effect":"Diarrhea"},{"rate":null,"effect":"Abdominal pain"},{"rate":null,"effect":"Nausea"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Atorvastatin is a statin that competitively inhibits HMG-CoA reductase, the rate-limiting enzyme in cholesterol synthesis, thereby reducing LDL cholesterol and triglycerides. Esomeprazole is a proton pump inhibitor that suppresses gastric acid production by irreversibly blocking the H+/K+-ATPase pump in parietal cells. The combination is designed to provide cardiovascular protection while mitigating gastrointestinal side effects associated with statin therapy.","oneSentence":"This combination drug lowers cholesterol by inhibiting HMG-CoA reductase (atorvastatin) while reducing gastric acid secretion by blocking the proton pump (esomeprazole).","_ai_confidence":"medium"},"_scrapedAt":"2026-03-27T23:30:24.644Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Hyperlipidemia with concurrent need for gastric acid suppression"},{"name":"Cardiovascular disease prevention in patients at risk for statin-induced gastrointestinal adverse effects"}]},"trialDetails":[{"nctId":"NCT00930670","phase":"PHASE4","title":"Evaluation of the Influence of Statins and Proton Pump Inhibitors on Clopidogrel Antiplatelet Effects","status":"COMPLETED","sponsor":"Centre de Recherche de l'Institut Universitaire de Cardiologie et de Pneumologie de Quebec","startDate":"2009-06","conditions":"Coronary Artery Disease","enrollment":320}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Atorvastatin-esomeprazole","genericName":"Atorvastatin-esomeprazole","companyName":"Centre de Recherche de l'Institut Universitaire de Cardiologie et de Pneumologie de Quebec","companyId":"centre-de-recherche-de-l-institut-universitaire-de-cardiologie-et-de-pneumologie","modality":"Small molecule","firstApprovalDate":"","aiSummary":"This combination drug lowers cholesterol by inhibiting HMG-CoA reductase (atorvastatin) while reducing gastric acid secretion by blocking the proton pump (esomeprazole). Used for Hyperlipidemia with concurrent need for gastric acid suppression, Cardiovascular disease prevention in patients at risk for statin-induced gastrointestinal adverse effects.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}